πŸ‡ΊπŸ‡Έ FDA
Patent

US 9505826

Modified antibody with improved half-life

granted A61PA61P1/00A61P1/04

Quick answer

US patent 9505826 (Modified antibody with improved half-life) held by TEVA PHARMACEUTICALS AUSTRALIA PTY LTD expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
Grant date
Tue Nov 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61P, A61P1/00, A61P1/04, A61P1/14, A61P11/00